Shares of MediciNova (MNOV), a small biotech, rose sharply Monday, but for a reason that may not hold up to scientific scrutiny.

MediciNova announced the early termination of a mid-stage study because of positive results in patients with NASH, or nonalcoholic steatohepatitis, a fatty liver disease. MediciNova shares rose 20 percent to $12.33.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • A cheap way to cut triglycerides is to consume less sugar. Treating the symptoms of a bad diet is not good medicine but slipstreaming the soft drinks industry is probably excellent business

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy